Xanomeline Enteric Capsule
Sponsors
Bristol-Myers Squibb
Conditions
Alzheimer DiseaseAlzheimer's DiseaseHealthy Volunteers
Phase 1
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
RecruitingNCT07011732
Start: 2025-07-10End: 2028-12-08Target: 426Updated: 2026-08-11
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
RecruitingNCT07011745
Start: 2025-07-16End: 2028-11-13Target: 426Updated: 2026-08-26